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Prevalence of peri-implant diseases – a 
critical review on the current evidence
Abstract: The objective of this paper was to evaluate the current 
evidence reporting on the prevalence of peri-implantitis and to 
determine the influencing factors. An electronic search for articles 
published until February 2019 reporting on the prevalence of 
peri-implantitis was performed in MEDLINE. Included criteria were 
published in international peer-reviewed journals, written in English 
language, reported on the prevalence of peri-implantitis, included 
implants with a minimum follow-up of one year after functional loading 
and used a clear definition for peri-implantitis and/or peri-implant 
mucositis with a clear cutoff for bone level changes according to the 
case definitions of Sanz and Chapple and Berglundh et al. 2018. 
Included papers were anaylized for factors affecting the reported 
prevalences for peri-implantitis. Twenty-five papers were included in 
the present review and a wide range for the reported prevalence of 
peri-implantitis was seen. Case definitions for peri-implantitis with 
various thresholds for bone loss together with the type of reporting on 
patient- or implant-level were the most significant factors that lead to a 
large variety of the occurrence of the disease. Additionally, follow-up 
time and the evaluation in a certain “convenience” population may 
have influenced the prevalence values. In conclusion, it can be stated 
that a wide range for reporting the prevalence of peri-implantitis can 
be found and no real estimation of the global burden of the disease 
can be made. Applying accurate case definitions for peri-implantitis is 
the most important factor for reporting the prevalence and should be 
strictly followed in future reports.
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Introduction
In the past two decades, dental implants have become a widely 
accepted and implemented therapeutical method to replace missing 
teeth and support fixed and partially removable prostheses. High long-
term survival rates have been reported both for systemically healthy 
(cumulative survival rates of 83.8% after 25 years, 96.1% after 10 years)1,2 as 
well as for medically compromised patients (i.e. oral cancer: cumulative 
survival rate after 20 years 90.8%).3 Despite the high survival rates and 
intensive periodontal and prosthetical maintenance over time, implant 
failures may occur.4,5,6 In the last decades, evidence on the presence of 
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peri-implant inflammations affecting both soft and 
hard tissues that may eventually lead to implant 
failure (loss) has substantially increased. These 
are seen as biological complications related to 
inflammatory conditions of the surrounding soft 
and bone tissues, which are induced by bacterial 
biofilm and are distinguished as peri-implant 
mucositis and peri-implantitis.7,8,9 
Peri-implantitis was firstly described in 1987 
by Mombelli et al.10 as an infectious disease 
with many common features to periodontitis. 
Considering the multiple etiological factors and 
clinical characteristics, many definitions arose 
and, from the clinical perspective, no consensus 
for a clear definition for peri-implantitis was 
settled. Peri-implantitis was mainly defined as 
an inflammatory response of the peri-implant 
mucosa with marginal bone loss, while peri-implant 
mucositis resumed to soft-tissues inflammation.11,12 
Discrepancies in case definitions and disease 
estimations on various convenience samples led 
to controversial reports on the prevalence of peri-
implant diseases.13,14 The lack of clear clinical 
parameters in these definitions led to a large range 
in the reported prevalence/incidence of peri-
implant diseases making thus difficult to estimate 
the real burden of these pathologies. Considering 
the definitions for incidence (“the number of new 
cases of a specific disease occurring during a certain 
period”) and prevalence of a disease (“the number 
of cases of a disease in existence at a certain time 
point”),15 the use of longitudinal studies has been 
proposed for assessing the incidence while that 
of cross-sectional studies for determining the 
prevalence of peri-implant diseases.11 Nonetheless, 
in november 2017 in the World Workshop on 
Periodontolgy (WWP), the European Federation of 
Periodontology (EFP) and the American Academy 
of Periodontology (AAP) reached a consensus and 
set clear a definition with clear clinical cutoff points 
for peri-implant pathologies both for the day-to 
day clinical practice as well as for epidemiological 
studies.16,17,18,19 
Therefore, the aim of the present review, was 
to critically analyze the available evidence for the 
prevalence of peri-implantitis in the light of the 
current definition of peri-implant diseases.
Methodology
A literature search for articles published until 
February 2019 reporting on the prevalence and/
or incidence of peri-implantitis and peri-implant 
mucositis was performed in MEDLINE via PubMed 
database. Included studies had to be: published in 
international peer-reviewed journals, written in 
English language, report on the prevalence and/or 
incidence of peri-implantitis and/or mucositis, 
include implants with a minimum follow-up of one 
year after functional loading and a clear definition for 
peri-implantitis and/or peri-implant mucositis with a 
clear cutoff for bone level changes (≥2/≥3 mm apical 
of the coronal part of the implant, in the absence 
of previous radiographic measurements, or bone 
loss beyond crestal bone level changes after initial 
bone remodeling after the first year of loading).9,16 
Results
The initial electronic search revealed 248 
publications; after abstract screening of the abstracts 
based on the inclusion criteria, 35 papers were 
selected for full-paper analysis. Included studies 
can be found in Table. Most of the papers considered 
in the definition for peri-implantitis a cutoff for 
bone loss of 2mm or calculated the bone loss from 
a level of 2–3 implant threads. Applying strictly all 
recommended definition criteria for peri-implantitis 
of the WWP 2017 (BOP/SUP, pocket depths ≥6mm, 
bone level ≥3mm of the most coronal portion of the 
intraosseous part of the implant) no single study can 
be taken into consideration.16 
Discussion
A wide range of prevalences for peri-implant 
biological complications has been reported in 
the literature so far. Reviews and meta-analyses 
from the past three years mention prevalences for 
peri-implant mucositis of 42.9%,13 of 29.48% (implant 
level) or 46.83% (patient-based);20 for peri-implantitis 
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Table. Included studies reporting on the prevalence of peri-implant mucositis and peri-implantitis.
No. Study Country
Study type
Case definitions for 
mucositis
Prevalence of 
mucositis
Prevalence of 
Peri-implantitis 
(PI)
Possible associated risk factors 
(implant type/surface, keratinized 
mucosa, history of periodontitis, 
diabetes, smoking, prosthetics)
Patients Peri-implantitis
Setting: University/
private practice
 
Evaluation period  
1
Aguirre-Zorzano 
et al. 2015 37
Spain
Cross-sectional Mucositis:
Patient level: 
24.7%
Patient level: 
15.1%
Stat. sign. association for 
plaque index, periodontitis 
and implant location with 
mucositis.
Retrospective 
BOP, clinical signs of 
inflammation, no BL 
(< 1.5 mm)
  
239 patients/786 
implants
PI: BOP, 
clinical signs of 
inflammation, BL (≥ 
1.5 mm)
Implant level: 
12.8%
Implant level: 
9.8%
Stat. sign. association for 
plaque index and implant 
location with PI.
university     
6–17y (mean 
5.3 y) functional 
loading
    
2
Canullo et al. 
2016 63 Spain
Cross-sectional Mucositis: n.r.
n.r.
Patient level: 
10.3%
Peri-implantitis implants 
showed higher % of plaque, 
of BOP, < 2mm attached 
gingiva, more cemented 
crowns, more bone-
augmented sites.
588 patients/1507 
implants
PI: PD≥4mm, BOP/
SUP, BL>3mm
Implant level: 
7.3%
 
university    
5.1 y    
3
Cecchinato et al. 
2014 31 Italy
Cross-sectional 
Mucositis: BOP, 
BL≤0.5 mm
Patient level: 
65%
Patient level: 
12% (within 
10 y)
n.r.
100 patients/ 291 
implants analysed
PI: PD≥4mm, 
BOP, BL>0.5mm 
from >1 year after 
loading
Implant level: 
69.8%
Implant level: 
5% (within 10 y)
Private practice    
≥ 8 y (mean 
10.7 y) functional 
loading
   
4
Daubert et al. 
2015 34
USA
Cross-sectional
Mucositis: BOP, 
gingival inflammation, 
no BL
Patient level: 
48%
Patient level: 
26%
Association betw. PI and 
diabetes and younger age at 
implant insertion, periodontal 
status at follow-up. 
96 patients/ 225 
implants
PI: BOP/SUP, 
BL≥2mm after 
initial remodeling, 
PD≥4mm
Implant level: 
33%
Implant level: 
16%
No association with smoking
university     
9–15 y (mean 
10.9 y)
    
Continue
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Continuation
5
Derks et al. 
2016 24
Sweden
Cross-sectional 
Mucositis: BOP/SUP, 
no BL
Patient level: 
32%
Patient level: 
45% Stat. sign. higher OR for 
moderate/severe PI for 
history of periodontitis (4.1), 
≥4 implants (15.1), in the 
mandibular region (2.0), 
distance between prosthetic 
restauration margin and 
initial crestal bone level ≤ 
1.5mm (2.3), for general 
practitioners as provider for 
prosthetics (4.3), certain 
brands of implants: Astra Tech 
(3.6, mostly TIOblast surface), 
Nobel Biocare (3.8, mostly 
TiUnite surface), Straumann 
(1, all SLA surface), remaining 
implant brands (5.56).
Retrospective   BL:
588 patients/2277 
implants
PI: BOP/SUP, BL (> 
0.5 mm)
Implant level: 
35.1%
> 2 mm: 14.5%
> 3 mm: 10.1%
   > 4 mm: 5.9%
university, private 
practice
Moderate/severe PI: 
BOP/SUP, >2mm BL
 
Implant level: 
24.9%
  
9 years functional 
loading
  BL:
   > 2 mm: 8.0%
   > 3 mm: 4.3%
   > 4 mm: 2.3%
6
Fransson et al. 
2005, 2008 64,65
Sweden
cross-sectional
Mucositis: BOP, 
BL≤0.6mm from  
1 year after loading
Patient level: 
n.r.
Patient level: 
27.8%
Smokers had a higher number 
of affected implants than 
non-smokers. 
662 patients 
/3413 implants- 
PI: BOP, bone 
level ≥3 threads & 
BL≥0.6mm from 1 y 
after loading
Implant level: 
> 90%
Implant level: 
12.4%
A higher proportion of 
peri-implant clinical pathology 
(SUP& PD≥6mm) in smokers 
than in non-smokers.
82 patients with 
clinical assessment 
/482 implants
    
university    
Higher frequency of peri-
implant clinical pathology 
(BOP, SUP, recession, 
PD≥6mm) at implants with 
progressive BL
5–20 y  
(mean 9.4y)
    
7
Francetti et al. 
2019 53 Italy
Cross-sectional Mucositis: n.r.
n.r.
Patient level: 
12.7 % (after 5y)
No sign. Risk factors: smoking 
(p=0.755), periodontitis 
(p=0.399)
77 patients/384 
implants
PI: BOP/SUP, 
BL>2mm
 
Private clinic  
Implant level: 
4.6% (after 5 y)
14.6% 
(after 5 y)13.7y 
(mean 8y)
  
8
French et al. 
2019 54 
Canada
Retrospective 
cohort study
Mucositis: Implant 
mucosal Index (IMI)
Implant level: 
38.6% (relaxed 
criteria)
Implant level:
Risk factors with effect on BL: 
autoimmune
 Strict criteria:≥2
14.2%  (strict 
criteria)(6.7y)
4.7% (relaxed 
criteria)
disease, heavy smoking, 
bisphosphonate therapy, 
implant location, diameter and 
design, and BL 
2060 patients/ 
4591 implants
Relaxed criteria≥1  
3.6%  (strict 
criteria)(6.7y)
 
private practice
PI: Mucositis + B 
L≥ 1 mm one y 
after installation
   
5 Mucositis+BL≥1 
mm one y after 
installation10 y 
(mean 6.7y)
    
Continue
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9
Katafuchi et al. 
2018 55
USA
Cross-sectional Mucositis: n.r.
n.r.
Implant level: 
16.7%
Emergence profile >30 degrees 
is a significant risk indicator for 
PI; convex profile additionally for 
bone-level implants.
83 patients/168 
implants
PI: BOP/SUO, 
BL≥2mm after 
initial remodeling, 
PD≥4mm
bone level 
implant: 22.8%
mean 10.9 y  
tissue level 
implants: 7.5%
  
Petient level: 
25.3%
  
Bone level 
implants: 28.9%
  
Tissue level 
implants: 14.8%
10
Koldsland et al. 
2010 &  
2011 32,66
Norway
Cross-sectional
Mucositis: 
inflammation 
(bleeding, BOP, SUP), 
no BL
Patient level: 
39.4%
Patient level: 
47.1%
n.r.103 patients/374 
implants
PI: inflammation 
(bleeding, BOP, 
SUP), BL (≥2mm, or 
≥3mm)
Implant level: 
27.3%
Implant level: 
36.6%
University  
1-16 y (mean 8.4y) 
functional loading
   
11
Konstantinidis  
et al. 2015 35 Germany
Cross-sectional
Mucositis: BOP, no BL 
(BL<2mm)
Patient level: 
64.5%
Patient level: 
12.9%
High plaque score (OR:1.36) 
was a risk indicator for 
mucositis, while soft- or hard-
tissue augmentation had a 
protective effect.
186 patients/ 597 
implants
PI: BOP, PD ≥ 5 mm, 
B L > 2 mm
Implant level: 
57.0%
Implant level: 
6.2%
Loss of the last tooth in the 
dentition (OR:1.06) and location 
in the maxilla (OR:1.05) were 
risk factors for peri-implantitis.
university     
1-16.5 y (mean 
5.5y)
    
12
Marrone et al. 
2013 56
Belgium
Cross-sectional
Mucositis: PD≤5mm, 
BOP, BL≤ 2mm
Patient level: 
31%
Patient level: 
37%
Age over 65y (OR:1.39), active 
periodontitis (OR: 1.98), hepatitis 
(OR: 2.92) and edentulism 
(OR:5.56) were associated with 
peri-implantitis.
103 patoents/266 
implants
PI: PD>5mm, BOP, 
BL>2mm
  
Sign. correlation between 
peri-implantitis and rough implant 
surfaces and overdentures.
private practice & 
university
 
Implant level: 
38%
Implant level: 
23%
 
5–18 y  
(mean 8.5y)
    
13
Meijer et al. 
2014 25
Netherlands
Prospective cohort 
study
Mucositis: BOP/SUP, 
BL<2mm
Incidence: Incidence:
n.r.
150 patients/ 275 
implants (5 y), 240 
implants (10 y)
PI: BOP/SUP,  
BL≥ 2mm
Patient level: Patient level:
university  51.9% (5 y) 16.9% (5 y)
5 and 10 y 
functional loading
57.0% (10 y) 29.7% (10 y)
Continue
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Mir-Mari et al. 
2012 48
Spain
Cross-sectional
Mucositis: BOP,  
BL< 2 implant 
threads
Patient level: 
38.8%
Patient level: 
16.3%
n.r.
245 patients/ 964 
implants
PI: BOP/SUP, BL≥2 
implant threads
Implant level: 
21.6%
Implant level: 
9.1%
private practice  
1–18 y (mean 
6.3 y)
   
15
Monje et al. 
2017 67
Spain
Cross-sectional
Mucositis: BOP/SUP, 
swelling, BL<2 mm
n.r. 
Patient level:
Stat. sign. association 
(p=0.04) betw. compliance 
to maintenance therapy and 
peri-implantitis.
115 patients/ 206 
implants
PI: BOP/SUP, redness, 
BL> 2mm
RC (regular 
compliers 3-6m 
recall): 4.5%
Compliance was associated 
with 86% fewer conditions of 
peri-implantitis.
Private practice
EC (erratic 
compliers: 
7-12m recall): 
26.3%
 
3–4.6 y (mean 
3.9y)
 
NC  
(non-compliers, 
no recall): 
14.3%
 
  Implant level:  
  RC: 2.4%  
  EC: 19%  
  NC: 8.7%  
16
Papaspyridakos 
et al. 2018 68
USA
Cross-sectional Mucositis: Implant level: Implant level:
High plaque index was 
associated stat. sign. with 
bone loss
 n.r.
31.5% (estim. 
5 y)
10% (estim. 5 y)
52 patients/457 
rough implants
PI:
63.0% (estim. 
10y)
20% (estim 10 y)
university
BL>2mm after 1st y 
of function/ >0.2mm 
per y, BOP/SUP
  
1–12y (mean 5.2y)    
17
Renvert et al. 
2014 58
Sweden
Cross-sectional, 
retrospective
Mucositis: BOP/SUP, 
edema, BL<2mm
Patient level: 
Patient level: 
63.7%  
(172 patients)
OR of having peri-implantitis 
was stat. sign for history of 
cardio-vascular disease (8.7) 
and of periodontitis (4.5). 
No association betw. PI and 
smoking or gender.
270 patients/n.r.
PI: PD≥4mm, BOP/
SUP, BL>2mm
36.3% -Peri-
implant health/
mucositis
University  
Mean 10.1 y 
functional loading
  
18
Renvert et al. 
2018 46
Sweden
Cross-sectional
Mucositis: BOP/SUP, 
no BL
Implant level: Implant level:
Patients with ≥3 implants at 
10 years had a higher risk for 
PI at 20 y.
218 patients  
(9–14 y)
PI: BOP/SUP, BL (3 
imp. threads)
82.6% (10y) 4.8% (10y)
No predictive value for PI 
at 20y for radiographic 
evidence of periodontitis, 
mucositis, smoking.
86 patients  
(20–26y)
 91.1% (20y) 10.8% (20y)  
university     
Continue
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Rinke et al. 
2011 69
Germany
Cross-sectional
Mucositis:  
PD ≥ 4 mm, BOP
Patient level: 
44.9%
Patient level: 
11.2%
Significant association betw. 
mucositis and smoking  
(OR: 3.77).
89 patients/n.r.
PI: PD ≥ 5 mm, 
BOP/SUP, BL
  
Significant association betw. 
peri-implantitis and smoking 
(OR:31.58) and compliance 
(OR:0.09).
private practice     
2–11y (mean 5.7y)     
20
Rokn et al. 
2016 36
Iran
Cross-sectional
Mucositis: BOP/SUP, 
BL ≤ 2 mm
Patient level: 
48.5%
Patient level: 
20%
Smoking (OR: 2.57) and lack 
of keratinized mucosa (OR: 
3.89) were associated with PI. 
134 patients/478 
implants  
(55% tissue level)
   
university
PI: BOP/SUP,  
BL> 2mm
Implant level:
Implant level: 
8.8%
1–11 y (mean 
4.4 y)
   
21
Roos-Jansaker et 
al. 2006 45
Sweden
Cross-sectional
Mucositis: PD≥4 mm, 
BOP, BL<1 thread
Patient level: 
48%
Patient level: 
16%
n.r.
216 patients/ 999 
implants analysed
PI: BOP/SUP,  
BL≥1.8 mm from 1 y 
after loading
Implant level: 
16%
Implant level: 
6.6%
university  
9–14y (mean 11y)    
22
Schwarz et al. 
2017 47
Germany
Cross-sectional
Mucositis: BOP,  
no changes at bone 
level compared to 
baseline
Patient level: 
41.6%
Patient level: 
13.9%
Plaque (OR: 8.4) and male 
gender (OR: 2.0) were 
associated with mucositis.
238 patients/ 512 
implants
PI: BOP/SUP, changes 
at bone 
Implant level: 
35.6%
Implant level: 
7.6%
Plaque (OR: 9.3) and smoking 
(OR: 2.7) were associated with 
peri-implantitis.
university
level compared to 
baseline
 
1–6.7y (mean 
2.2 y)
    
23
Simonis et al. 
2010 51
France
Retrospective 
cohort study
Mucositis: n.r.
n.r.
Patient level:
History of periodontitis increases 
the risk for peri-implantitis 
(OR:5.1).
55 patient/131 
implants
 
With 
periodontitis: 
37.93%
university
PI: PD≥5mm,  
BOP/SUP, BL≥2.5mm 
or BL≥3 threads for 
at least 10y
Without 
periodontitis: 
10.53%
10-16y  
Implant level: 
16.94%
24
Tenenbaum et al. 
2017 70
France
Prospective cohort 
study
Mucositis: BOP, no BL
Patient level: 
73.1%
Patient level: 
15.4%
Some bacteria were associated 
with worsened clinical situation.
52 patients/108 
implants
PI: PD≥5mm, BOP, 
BL (Progressive BL: 
4.5mm)
  
university  
Implant level: 
60.2%
Implant level: 
12%
10.8y    
Continue
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values vary significantly between those reported 
on implant level (21.7%,13  9.25%,20 1.1–85%,21 12.8%22) 
and those on patient level (19.83%,20 0–39.7%,23 
18.5%22). For longer evaluation periods (over 9 years 
of functional loading) data from a retrospective 
and cross-sectional analysis show a prevalence for 
peri-implantitis of 45% (patient level, 14.5% of these 
patients with moderate to severe disease24 and 57% 
after 10 years of function.25
Methodological inconsistencies and shortcomings 
of the reporting studies9,14,26 led to these significant 
variations of the prevalence for peri-implant diseases 
making thus difficult to globally estimate the real impact 
of peri-implant biological complications. Despite the 
recommendations for quality improvement in peri-
implant disease research of the VIII-th EWP,9 only few 
study protocols have applied these. Since 2018, according 
to the new classification of periodontal diseases of the 
WWP 201716 clear definitions for peri-implant health, 
mucositis and peri-implantitis were made and these 
should ease and assure a more reliable evaluation of 
the prevalence, extent and severity of peri-implant 
diseases in epidemiological studies. Nonetheless, 
after the search of the current review, no single study 
applied entirely the newly proposed definition criteria 
for peri-implantitis (BOP/SUP, pocket depths ≥6mm, 
bone level ≥3mm of the most coronal portion of the 
intraosseous part of the implant) 16. Either bone loss 
thresholds were unclearly defined, or related to 2 mm 
bone los or to implant threads, and/or lower values 
for included peri-implant pocket depths (i.e., 4 or 5 
mm) were used (Table).
Analyzing closer the current evidence, following 
factors may affect the reported prevalence of peri-
implant diseases.
Definition of peri-implantitis
More than two decades ago, peri-implantitis has 
been defined as an infectious pathological condition 
of the peri-implant tissues.10,27 Following the 1st 
European Workshop on Periodontology (EWP) in 
1993 described the term peri-implantitis in relation 
to inflammatory processes at osseointegrated dental 
implants with the clinical signs of pocket formation 
and bone resorption following the anticipated initial 
bone remodeling.12 This definition is nowadays still 
correct and applicable. Nonetheless, the lack of clear 
thresholds to define pathological values for peri-
implant pocket depths and loss of the supporting bone 
after functional loading led to various applications 
of this definition in clinical studies assessing the 
prevalence, incidence and extent of peri-implantitis. 
Therefore, in the VIIIth EWP in 2012 it was agreed that 
the presence of clinical inflammation together with 
a peri-implant bone level of 2mm from the expected 
level after bone remodeling should be considered as 
criteria for defining peri-implantitis in clinical studies.9 
When reporting incidence and baseline radiographs 
are available, the bone loss cutoff is set at 1–1.5mm.9 
Despite these guidelines, the definitions used 
in clinical studies were inconsistent: most studies 
used the same threshold for peri-implant pocket 
depths (>5mm), but the various levels for bone loss 
resulted in a large range of disease occurrence. 
Studies reporting low prevalences for peri-implantitis 
(implant level) used a high bone loss thresholds: 
for bone loss of 5 mm 1%,28 8.80–22.20%;29 for bone 
loss ≥3mm: 9%,30 0.37%.28 On the other side, high 
prevalences were obtained when bone loss was set 
at low values (< 1.5mm) or was not mentioned: 77% 
(0.5 mm),31 47% (0.4mm).32 Logically, different bone loss 
Continuation
25
Zetterqvist et al. 
2010 28
Multicenter 
(Europe: 
Sweden, 
Italy, USA)
RCT Mucositis: n.r.
n.r. 
Patient level: 1%
After 5 y no increased risk 
of peri-implantitis for fully 
etched implants compared to 
hybrid-designed implants.
112 patients/  
304 implants 
PI: PD > 5 mm, BOP, 
SUP, BL > 5 mm from 
loading
Implant level: 
0.4%
after 5 y:  
96 patients 
  
university   
5 y   
PD: pocket depth; BOP: bleeding on probing; SUP: suppuration; BL: bone loss; n.r.: not reported; stat. sign.: statistiscally significant; 
PU: peri-implantitis; KMW: keratinized mucosa width; OR: odds ratio; RCT: randomized controlled trial; y: years
8 Braz. Oral Res. 2019;33(suppl):e063
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thresholds reflect various degrees of disease severity 
and if these define the disease, then consecutively 
its prevalence is miscalculated. Thus, uniformity in 
the reported prevalence can be seen when studies 
used the same bone loss levels: for bone loss 1.5–3mm 
14.5%,24 12.9%,25,33,34,35,36,37, 8.8%,36 7.3%,33 6.2%,35 14.3%. 29 
Considering the new Classification for peri-
implant conditions of the WWP 2017, reporting 
the prevalence and incidence for plaque-induced 
peri-implant diseases should be more homogenous 
and shall provide a realistic view of the global burden 
of peri-implant diseases.16,17,19
Timepoint of assessment 
Both peri-implant mucositis and peri-implantitis 
have an infectious etiology based on the accumulation 
of a biofilm composed of periodontal pathogens 
on the implant surface.17,38,39,40,41 It is believed that 
peri-implant mucositis is the precursor for peri-
implantitis, however, the histopathological and 
clinical conditions initiating this conversion are still 
not elucidated.19 Since peri-implantitis represents 
rather a chronic form of disease implying time for the 
osseous destruction, it seems appropriate to report 
on the prevelance of peri-implantitis after sufficient 
time in function. Analyzing the existing reports 
with respect to timepoint of evaluation, it seems that 
prevalences of peri-implantitis do not vary strongly.
Studies evaluating the prevalence of peri-
implantitis after 5 years of function and for a 
bone-loss threshold over 2 mm report similar 
values (implant level) compared to those for longer 
observation periods (over 9 years): at 5 years 12.9%,35 
16.9%,25 9.6%,42 8.80%,36 10.9%,43 1.80%;44 at over 9 years: 
9%,30 6.6%,45 16%– 26%,34 14.5%24 and 29.7%.25 The 
differences that can be seen in the above mentioned 
values relate to the different thresholds for bone loss 
that was included in the case definition (0.5 mm vs. 
> 2 mm), highlighting again the importance of a 
consensus in the establishing a clear cutoff for peri-
implant bone loss. Renvert et al.46 reported on the 
prevalence of peri-implant diseases with the longest 
follow-up of over 20 years in function and obtained 
similar values to those reported in the literature for 
10 years: peri-implantitis 22.1%. Thus, the present 
data suggest that function time has only a limited 
effect on the development of peri-implantitis.13,14,32 
Nonetheless, it seems relevant that clinical studies 
assessing the prevalence of peri-implantitis include 
cases with similar periods of function. Several 
studies mixed shorter with longer loading periods: 
6 months -17 years,37 10–46 months,47 1–14 years,33 
1–11 years,36 1–18 years,48 which may have lead to a 
possible underestimation of the reported prevalence/
incidence of peri-implantitis. 
Level of reporting: implant vs. subject level
Assessing the global burden of peri-implant 
diseases is a matter of patients/humans as in any 
other chronic systemical diseases. When prevalences 
of any type of disease are reported, these refer to 
the number of subjects affected by that disease at 
that moment. Therefore, it seems quite appropriate 
to similarly evaluate the prevalence of peri-implant 
pathologies at a subject level. This was also stressed 
out in 2012 at the VIII-th EWP consensus workshop 
where the impact of peri-implant diseases on 
individuals should be in the focus and not that 
on individual implants. Research assessing the 
prevalence of peri-implant diseases should be thus 
evaluated on subject-level analysis.9
Several previous clinical studies reported the 
prevalence only on implant-level making thus 
difficult to estimate the global impact of the 
disease.28,49,50,51 Moreover, higher prevalences are 
reported on patient-level as opposed to implant-
level: 14.5% vs. 8.0%,24 16.4 % vs. 7.3%,33 2.5 vs. 0.9,52 
12.7% vs. 4.6,53 4.7 % vs. 3.6%,54 25.3% vs. 16.7%.55 
However, in the past 5 years, the majority of clinical 
studies reporting on the prevalence of peri-implantitis 
applied the recommendations of the VIII-th EWP 
and included patient-level analyses. 24,25,33,34,35,37,53,54,55
Evaluated population
The majority of the studies reported prevalences 
for peri-implant diseases investigating patients either 
from university or from private clinics.28,31,48,56 These 
analyses rely however on “convenience samples” of 
various size bearing with it a high sensitivity for 
selection bias not representing the global/common 
implant population.26,57 Only few studies reported 
the prevalence based on random patient selection24 or 
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based on multicenter data from subjects in private and 
university clinics24,47,58 or. The VIIIth EWP from 2012 
recommended for evaluations in clinical studies of the 
prevalence of peri-implant diseases random patient 
selection from multivariate treatment environments 
of adequate sample sizes.9,26 
Various prevalences for peri-implantitis have 
been reported when populations with additional 
of conditions (i.e., diabetes, rheumatoid arthritis, 
smokers, history of periodontitis, adherence to 
maintenance therapy) have been investigated to 
assess risk factors of developing peri-implantitis. 
Prevalence in patient with a history of periodontitis 
seem have a higher prevalence of the disease which 
remains stable over time; thus, studies evaluating 
the presence of peri-implantitis under 5 years of 
function report values of 14.3–26.1% (bone loss>2mm) 
or 8.9–17.4% (bone loss > 3 mm) as opposed to 6.1% 
or 3% in patients without residual periodontitis.29 
Similar values were observed also in more severe 
cases with bone loss > 5 mm (22.2%, after 7.9 years)50 or 
> 0.2 mm annual bone loss at 8.25 y (26%).59 Similarly, 
in non-smokers implant level based prevalence of 
peri-implantitis reached 7.44% for a functional loading 
period of 6 months–5 years60 and 9% after 10 years.30 
Additionally, higher prevalences were reported 
for patients not attending a maintenance program 
(28.80%)43 as opposed to those in regular prophylaxis 
(after 5 years: 10.8%, 1.8%; after 10 years: 9%).30,43,44 
Another type of population with various reports 
on the prevalence of peri-implantitis are diabetic 
patients. Ferreira et al.60 reported a prevalence 
(patient-level) of 24% as opposed to 7% of non-diabetic 
patients. On the other side, Tawil et al.61 reported 
occurrence (4.25%) of peri-implantitis only in poor 
controlled diabetes (HbA1c level 7-9%). Whether 
these patient conditions represent risk factors for 
developing peri-implantitis is to be discussed in a 
further paper of this issue. 
Implants placed in pristine vs. 
augmented sites
Outcome of a recent systematic review62 indicated 
that implants placed in augmented sites performed 
slightly less effective after a mean observation 
period of at least 10 years compared with implants 
placed in pristine bone when assessing peri-
implantitis (17.8% vs. 10.3%) and implant failure 
rates (3.6% vs. 2.5%), respectively. Patient samples 
included in that systematic review,62 however, 
differed with respect to clinical characteristics such 
as history of treated periodontitis and materials 
used for augmentation procedures. Moreover, none 
of the studies including augmentation procedures 
adopted the same surgical protocol, thus enhancing 
heterogeneity due to sample selection. Hence, 
considering the lack of representation of various 
augmentation techniques used and of the variety 
of implant designs, the results of that systematic 
review 62 should be interpreted with caution.
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